On May 1, 2025 Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, reported that Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at The Citizens Life Sciences Conference on Thursday, May 8, 2025, at 10:00 a.m. ET in New York, NY (Press release, Nuvation Bio, MAY 1, 2025, View Source [SID1234652467]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Nuvation Bio website at View Source An archived recording will be available for 90 days following each event.

On May 1, 2025 Mythic Therapeutics, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, reported that updated dose escalation results from its Phase 1 KisMET-01 study evaluating its investigational cMET-targeting ADC, MYTX-011, in patients with previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC), will be presented at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Mythic Therapeutics, MAY 1, 2025, View Source;utm_medium=rss&utm_campaign=mythic-therapeutics-to-present-updated-dose-escalation-data-from-phase-1-kismet-01-study-on-mytx-011-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting [SID1234652449]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re encouraged by the updated dose escalation results from the KisMET-01 study, which demonstrate the potential of MYTX-011 to offer a new therapeutic option for patients with advanced NSCLC," said George Eliades Ph.D., President and Chief Executive Officer at Mythic Therapeutics. "We’re excited to share these promising data with the oncology community at ASCO (Free ASCO Whitepaper) and to continue driving the development of MYTX-011 forward."

Details of the presentation are as follows:

Abstract Title: MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study.
Presenter: Rebecca Heist, M.D., M.P.H., Medical Oncologist, Massachusetts General Hospital, Cancer Center
Format: Poster Session
Session Name: Lung Cancer – Non-Small Cell Metastatic
Session Date and Time: Saturday, May 31, 2025, at 1:30 – 4:30 PM CDT
Poster Board Number: 93
Abstract Number: 8613

About MYTX-011

MYTX-011, an investigational cMET-targeting ADC, leverages Mythic’s innovative FateControl technology which is designed to allow ADCs to actively navigate inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells. This breakthrough approach takes the next step beyond linker-payload technologies and is designed to improve ADC efficacy against a broad set of molecular targets and patient profiles. MYTX-011 is currently being evaluated in the Phase 1 KisMET-01 clinical trial, a first-in-human, open-label, multi-center, dose escalation and dose expansion study enrolling patients with locally advanced, recurrent or metastatic NSCLC (NCT05652868).

On May 1, 2025 Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, reported that its management team is scheduled to participate and present at the following investor conferences in May (Press release, Verastem, MAY 1, 2025, View Source [SID1234652468]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 3rd Annual BioConnect Investor Conference: Fireside chat on Tuesday, May 20 at 12:00 pm ET
2025
RBC Capital Markets Global Healthcare Conference: Fireside chat on Tuesday, May 20 at 3:35 pm ET
Alliance Global Partners/A.G.P.’s Annual Healthcare Company Showcase: Virtual fireside chat on Wednesday, May 21 at 10:20 am ET
A live webcast of the fireside chats can be accessed under events on Verastem Oncology’s website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.

On May 1, 2025 NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, reported a business update and provided first quarter 2025 financial results (Press release, NextCure, MAY 1, 2025, View Source [SID1234652450]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With our LNCB74 antibody-drug conjugate ("ADC") program completing cohort 2 in April 2025, we are progressing as planned through the dose escalation portion of the Phase 1 study. We expect to be in a position to initiate backfill cohorts in the second half of the year with 10 active investigator sites, and an additional 3 sites projected to be onboard in May 2025. We plan to provide a proof of concept data readout in the first half of 2026," said Michael Richman, NextCure’s president and CEO.

Business Highlights and Near-Term Milestones

LNCB74 (B7-H4 ADC)

● Dosed our first patient in January 2025 in the Phase 1 trial, cleared cohort 2 in April 2025 and currently dosing cohort 3.
● Expanded clinical footprint for the LNCB74 study with a total of 10 active trial sites.
● Plan to initiate backfill cohorts in the second half of 2025.
● Plan to provide a proof of concept data readout in the first half of 2026.

Preclinical Non-Oncology Programs Seeking Partnering

● Preclinical data for NC181 (ApoE4), a humanized antibody for the treatment of Alzheimer’s disease, has demonstrated amyloid clearance, prevention of amyloid deposition, plaque clearance and reduced neuroinflammation.
● Preclinical data for NC605 (Siglec-15), a humanized antibody for the treatment of osteogenesis Imperfecta (OI), has demonstrated that NC605 treatment reduced bone loss and enhanced bone quality in mice with OI.
● Both programs could lead to investigational new drug (IND) filings within 12 to 18 months if financial support from partners or third parties is secured.

Financial Results for Quarter Ended March 31, 2025

● Cash, cash equivalents, and marketable securities as of March 31, 2025 were $55.9 million as compared to $68.6 million as of December 31, 2024. The decrease of $12.8 million was primarily due to cash used to fund operations. We expect current financial resources to be sufficient to fund operating expenses and capital expenditures into the second half of 2026.
● Research and development expenses were $7.9 million for the three months ended March 31, 2025, as compared to $11.4 million for the three months ended March 31, 2024. The decrease of $3.5 million was due to lower costs related to programs other than LNCB74, lower preclinical development costs and lower personnel-related costs resulting from the restructuring and reduction-in-force announced during the first quarter of 2024 (the "2024 Restructuring").
● General and administrative expenses were $3.7 million for the three months ended March 31, 2025, as compared to $4.4 million for the three months ended March 31, 2024. The decrease of $0.6 million was primarily related to lower personnel costs and lower insurance costs resulting from the 2024 Restructuring.
● There were no restructuring and asset impairment costs for the three months ended March 31, 2025 as compared to $2.5 million for the three months ended March 31, 2024, which costs resulted from the 2024 Restructuring.
● Net loss was $11.0 million for the three months ended March 31, 2025, as compared to a net loss of $17.1 million for the three months ended March 31, 2024 due to lower costs as described above.

On May 1, 2025 Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next ​generation RNA precision manufacturing platform, reported its participation in two premier industry events this May: the 3rd mRNA Process Development & Manufacturing Summit Europe in Berlin and the 2025 TIDES USA Conference in San Diego (Press release, Nutcracker Therapeutics, MAY 1, 2025, View Source [SID1234652469]). The company will also serve as an Official Expertise Partner for the Process Development & Manufacturing Summit Europe and an Associate Sponsor of TIDES USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

3rd mRNA Process Development & Manufacturing Summit Europe

Location: Hotel Palace Berlin, Berlin, Germany

Dates: May 6–8, 2025

Nutcracker Therapeutics’ Director of Biochip Research and Development, Babak Sanii, will present the company’s approach to rapid, personalized mRNA manufacturing using its proprietary NMU-Symphony platform. The talk will highlight how the company’s fully integrated, end-to-end microfluidic manufacturing process enables the production of personalized cancer therapies (PCTs) in as little as three weeks — from RNA design to patient-ready injectable vials. The use of single-use biochips ensures a closed, sterile system that eliminates the risk of patient-to-patient cross-contamination, supporting both scalability and safety in PCTs.

Presentation Title: End-to-End Microfluidic Manufacturing of Personalized Cancer Treatments

Presenter: Babak Sanii, director of biochip research and development
Date & Time: May 8, 2025, at 2:00 PM (local time)
Session: Scaling mRNA Manufacturing: Seamless Transitions from Lab to Market to Ensure Consistent Quality for Meeting Growing mRNA Vaccine & Therapeutic Demands
2025 TIDES USA

Location: Manchester Grand Hyatt San Diego, San Diego, CA

Dates: May 19–22, 2025

At TIDES USA, Colin McKinlay, senior director of chemistry and delivery technologies, will showcase Nutcracker Therapeutics’ suite of proprietary technologies, including BaseCracker for antigen construct design, CodonCracker for RNA sequence optimization, and its novel Nutshell delivery vehicles — all key elements in assembling PCTs. These tools are seamlessly integrated into NMU-Symphony, which enables fully enclosed synthesis of RNA drugs with quality, speed, and scalability.

Presentation Title: mRNA Manufacturing on the NMU-Symphony — A Rapid End-to-end Platform for the Design, Microfluidic Synthesis, and Delivery of Personalized Cancer Therapeutics

Presenter: Colin McKinlay, senior director, chemistry and delivery technologies
Date & Time: May 21, 2025, at 1:30 PM (local time)
For more information about these conferences, please visit the mRNA Process Development and Manufacturing Summit Europe and the TIDES USA websites. In addition, please visit Nutcracker Therapeutics’ CRDMO webpage for more information about its services.